Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar's Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) signed a distribution agreement with International Medical Company to expand Sky Premium Life nutraceuticals in Qatar. IMC placed an initial purchase order of 31,000 units. Kulud Pharmacies, IMC's retail arm, is Qatar's largest pharmacy chain, providing nationwide reach.
Positive
- Distribution agreement for Sky Premium Life in Qatar with IMC
- Initial purchase order of 31,000 Sky Premium Life units
- Access to Kulud Pharmacies, Qatar's largest pharmacy chain with 130+ branches
- IMC to handle sales, marketing, regulatory, logistics, supply, distribution in Qatar
- Supports international expansion strategy across Gulf markets
Negative
- None.
News Market Reaction – COSM
In the Jun 26 session, COSM declined 7.07%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.1% during that session. Argus tracked a trough of -16.4% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-06-25 | Patent expansion | Positive | -10.9% | Advanced CCX0722 hydrogel patent application across major global weight management markets. |
| 2026-06-24 | Hospital sales update | Positive | -0.9% | Reported strong C-Sept PRO traction with high-margin, recurring hospital revenue in Greece. |
| 2026-06-22 | Manufacturing orderbook | Positive | -4.2% | Built contract manufacturing orderbook over 25M units with multi-year EU and international deals. |
| 2026-06-17 | Dermatology contract | Positive | -3.2% | Signed five-year Pharmex deal for 2.86M dermatology units to boost recurring manufacturing revenue. |
| 2026-06-15 | U.S. portfolio update | Positive | +14.2% | Outlined 18 Series nutraceuticals with projected $22.7M+ annualized revenue and ~$17.0M gross profit. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent 'crypto'-tag news has mostly been positive operational updates but the stock has declined after 4 of the last 5 releases.
Key Terms
nutraceuticals medical
regulatory affairs regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, June 26, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a distribution agreement with International Medical Company ("IMC") to expand its presence in the State of Qatar for its proprietary Sky Premium Life® line of nutraceuticals and food supplements. In connection with the agreement, IMC has placed an initial purchase order of 31,000 units.
Founded in 1998, IMC is Qatar's fastest-growing pharmaceutical retailer and distributor and one of the sector's leading employers, with a team of over 1,400 operating across its Sales & Marketing, Pharmacy, and Consumer divisions. Its retail arm, Kulud Pharmacies, is the largest pharmacy chain in the country, with over 130 branches and a portfolio of more than 12,000 products. The partnership gives Sky Premium Life broad consumer reach from the outset, supported by an established nationwide retail network.
The agreement marks a further step in Cosmos Health's international expansion of Sky Premium Life across high-growth Gulf markets. Under its terms, IMC will manage all key functions in the territory, including sales and marketing, regulatory affairs, logistics, supply, and distribution.
Greg Siokas, CEO of Cosmos Health, stated: "Qatar is one of the Gulf's most dynamic healthcare markets, and partnering with IMC and its Kulud Pharmacies network puts Sky Premium Life directly in front of consumers at scale from day one. This is exactly the kind of high-impact partnership we are pursuing as we accelerate Sky Premium Life's global growth.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ef90832-64c8-4caa-9750-36188d238105
